Background <p>Dual anti-CTLA-4/PD-1 inhibitors show efficacy in numerous malignancies. We are the first to report on the efficacy of ipilimumab-nivolumab immunotherapy in a dedicated cohort of patients with gynecologic clear cell carcinomas (CCCs), which are rare, aggressive cancers.</p> Methods <p>DART is a multicenter, multicohort phase II trial of ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg intravenously…
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix
Journal for ImmunoTherapy of Cancer | | Chae, Y. K., Othus, M., Patel, S. P., Backes, F. J., OMalley, D. M., Cristea, M., Naing, A., Kurnit, K., Eskander, R. N., T Goodrich, S., Robinson, W. R., Scalici, J., Chan, J., Ali-Ahmad, H., Hays, J., McCormick, C., Kim, E. J., Sueblinvong, T., Ahmed, A., Siedel, J., Thomes Pepin, J., Bottsford-Miller, J. N., Fagbemi, S. O., Jaslowski, A. J., Kim, H. S., Chung, L. I.-Y., Moloney-Lineen, C., McLeod, C. M., Chen, H. X., Sharon, E., Streicher, H., Ryan, C. W., Blanke, C. D., Kurzrock, R.
Topics: cervical-cancer, immunotherapy, clinical-trials
Read the full article at Journal for ImmunoTherapy of Cancer